This was materially ahead of the bar, not just a favorable year-over-year comparison. Pre-report published expectations were roughly $1.86-$1.87 in adjusted EPS and about $100.1 billion of revenue. CVS delivered $2.58 and $106.1 billion, respectively—a roughly $0.71-$0.72 EPS beat and about $6 billion more revenue than expected.
| Metric | Q2 2026 actual | Q2 2025 | Published expectation / prior outlook |
|---|---|---|---|
| Revenue | $106.1B | $98.9B | ~$100.1B consensus (Financial Highlights) |
| Adjusted EPS | $2.58 | $1.81 | ~$1.86-$1.87 consensus (Adjusted EPS reconciliation) |
| GAAP diluted EPS | $2.31 | $0.80 | — (Financial Highlights) |
| Adjusted operating income | $5.16B | $3.81B | — (Consolidated results) |
| Health Care Benefits adjusted operating income | $2.43B | $1.31B | — (Health Care Benefits segment results) |
| Medical benefit ratio | 87.4% | 89.9% | — (Health Care Benefits segment results) |
| Full-year adjusted EPS guidance | $7.90-$8.10 | — | $7.30-$7.50 prior company range; published FY consensus had been about $7.3-$7.4 (2026 Guidance; Q1 2026 guidance) |
| Cash flow from operations guidance | At least $11.5B | — | At least $9.5B prior company floor (2026 Guidance) |
The outlook increase is the larger signal. The new $7.90-$8.10 adjusted-EPS range is a $0.60 lift from the prior $7.30-$7.50 range, placing even its low end above the pre-results full-year expectation. That changes the question from whether the turnaround can hold to how much of the stronger insurance and retail-pharmacy profitability is sustainable through the second half. (2026 Guidance; Q1 2026 guidance)
Aetna’s margin recovery delivered the biggest upside—but the comparison is not all clean. Health Care Benefits adjusted operating income rose $1.12 billion to $2.43 billion as the medical benefit ratio improved 250 basis points to 87.4%; a lower ratio means less premium revenue was consumed by members’ medical costs. Yet $471 million of the increase reflects the absence of a prior-year Medicare Advantage premium-deficiency reserve. The underlying margin improvement is still meaningful, but the headline 85.5% profit growth overstates the recurring run-rate gain. (Health Care Benefits segment results)
The beat was broad enough to matter beyond insurance. Health Services profit rose 10.0% to $1.73 billion despite its adjusted operating margin slipping to 3.3% from 3.4%, while Pharmacy & Consumer Wellness profit rose 10.2% to $1.48 billion on stronger core pharmacy performance and acquired Rite Aid prescription files. Retail revenue itself grew only 0.7%, so the important result is better profitability and script volume—not a broad consumer-sales acceleration. (Health Services segment results; Pharmacy & Consumer Wellness segment results)
Cash generation reinforces the raised outlook, with one caveat. Six-month operating cash flow reached $10.6 billion, already above the old full-year minimum, and CVS repaid $3.29 billion of long-term debt. But $2.20 billion of cash flow came from working-capital movements, so not all of the year-over-year cash increase should be treated as recurring operating improvement. (Cash Flow statement)
Net: a clear upside reset versus expectations. The quarter beat decisively on both revenue and earnings, and the guidance raise validates that management sees more than a one-quarter windfall. The remaining tension is that Health Services margin remains under pressure and part of Aetna’s year-over-year gain reflects a favorable comparison, but neither offsets the scale of the reported beat or the $0.60 full-year earnings lift.
Read the original 8-K on SEC EDGAR ↗